Loading...
XNASAPYX
Market cap58mUSD
Jan 08, Last price  
1.55USD
1D
-9.36%
1Q
29.17%
Jan 2017
-56.82%
Name

Apyx Medical Corp

Chart & Performance

D1W1MN
XNAS:APYX chart
P/E
—
P/S
1.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.15%
Rev. gr., 5y
25.69%
Revenues
52m
+17.61%
20,495,10120,211,14126,676,18228,779,15728,096,51026,953,44724,230,00025,411,00027,671,00023,660,00027,681,00029,520,00036,627,00038,883,00016,686,00028,154,00027,711,00048,517,00044,510,00052,349,000
Net income
-19m
L-19.61%
1,511,993406,2082,683,2062,400,5911,831,788595,522-1,535,000109,000617,000-4,339,000-17,282,000-5,370,000-3,950,000-5,062,00064,009,000-19,650,000-11,906,000-15,200,000-23,278,000-18,713,000
CFO
-5m
L-74.12%
2,043,987-189,6222,986,2182,041,344742,829-98,332-566,0001,897,000165,000-2,536,000-417,000-5,786,000-2,837,000-3,704,000-21,011,000-18,475,000-16,066,000-10,449,000-20,280,000-5,249,000
Earnings
Mar 19, 2025

Profile

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
URL
https://apyxmedical.com/
IPO date
Jul 22, 1983
Employees
276
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
52,349
17.61%
44,510
-8.26%
Cost of revenue
72,300
70,372
Unusual Expense (Income)
NOPBT
(19,951)
(25,862)
NOPBT Margin
Operating Taxes
(2,432)
367
Tax Rate
NOPAT
(17,519)
(26,229)
Net income
(18,713)
-19.61%
(23,278)
53.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,718
365
BB yield
-3.00%
-0.45%
Debt
Debt current
734
253
Long-term debt
43,450
1,339
Deferred revenue
1,246
1,408
Other long-term liabilities
198
181
Net debt
532
(8,600)
Cash flow
Cash from operating activities
(5,249)
(20,280)
CAPEX
(533)
(1,010)
Cash from investing activities
6,734
(1,010)
Cash from financing activities
32,166
217
FCF
(10,600)
(31,175)
Balance
Cash
43,652
10,192
Long term investments
Excess cash
41,035
7,966
Stockholders' equity
(54,192)
(35,489)
Invested Capital
121,426
75,422
ROIC
ROCE
EV
Common stock shares outstanding
34,622
34,516
Price
2.62
11.97%
2.34
-81.75%
Market cap
90,710
12.31%
80,767
-81.65%
EV
91,463
72,378
EBITDA
(19,259)
(24,972)
EV/EBITDA
Interest
2,478
15
Interest/NOPBT